Table 1 Summary of registered clinical trials involving stem cell therapy for diabetes
From: From bench to bedside: future prospects in stem cell therapy for diabetes
Product | Introduction | Protocol/Trial ID | Trial phase | Trial status | Disease | Countries |
|---|---|---|---|---|---|---|
VC-01 | Â | NCT04678557 | I/II | Terminated | Type 1 | United States |
VC-01 | Pancreatic Endodermal Cells (PEC-01) with Recyclable Semi-Permeable Encapsulated Device Drug Delivery System | NCT02939118 | II | Completed | Type 1 | Canada; United States |
VC-01 | Â | NCT02239354 | I/II | Terminated | Type 1 | Canada; United States |
VC-02 | Â | NCT03162926 | I | Completed | Type 1 | Canada |
VC-02 | Improved vascularization and immunoprotection based on VC-01 | TrialTroveID-364656 | I | Terminated | Type 1 | Belgium |
VC-02 | Â | NCT03163511 | I/II | Completed | Type 1 | Belgium; Canada; United States |
VCTX210A | Pancreatic endodermal cells (PEC210A) derived from human embryonic stem cells (hESC) were used and genetically modified by CRISPR/Cas9 technology | NCT05210530 | I | Completed | Type 1 | Canada |
VCTX211 | VCTX211 is a human embryonic stem cell (hESC)-based pancreatic endodermal cell (PEC) product cell therapy and genetic engineering technology | NCT05565248 | I/II | Open | Type 1 | Canada |
VX880 | VX880 is a fully differentiated hESC-derived islet cell product | NCT04786262 | I/II | Open | Type 1 | Canada; France; Germany; Italy; Netherlands; Norway; Switzerland; United Kingdom; United States |